Anagrelide HCl

Research use only, not for human use.

Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.

Anagrelide hydrochloride, also known as Agrylin, is a drug used for the treatment of essential thrombocytosis---overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. Anagrelide controlled release (GALE-401) is in phase III clinical trials by Galena Biopharma for the treatment of essential thrombocytosis.

Cell Viability Assay Cell Line:Megakaryocytic and non-megakaryocytic cells Concentration:0.05, 0.3, 1 μM Incubation Time:12-dayResult:Inhibited only megakaryocytic cell growth at every concentration tested.Cell Cytotoxicity Assay Cell Line:GIST882 and GIST48 cell line Concentration:0.1, 1, 10, 100, 1000, 10000 nM Incubation Time:Result:Induced a cytotoxic effect in the GIST882 cell line (IC50= 16 nM), but was only weakly active in the GIST48 cell line.

Animal Model:Adult female athymic mice bearing GIST2B, GIST3, GIST9, GIST882 model Dosage:5 mg/kg Administration:Twice daily; for 10 days Result:Inhibited or reduced tumor growth in three (GIST2B, GIST9, GIST882) of these four models.

Anagrelide hydrochloride | BL 4162A | GALE-401 | Thromboreductin

Microbiology/Virology

HIV

PDE

Inflammation/Immunology

——

58579-51-4

292.55

C10H7Cl2N3O·HCl

>98% (HPLC)

DMSO : 7.69 mg/mL 26.29 mM; H2O : < 0.1 mg/mL

Cl.ClC1=CC=C2NC3=NC(=O)CN3CC2=C1Cl

Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride

(-20℃)

With Ice Pack

≥ 2 years